#HXN-1001
LightNews LightNews
newsen.bsky.social
Earendil Labs Marks Milestone with First Patient Doses in IBD Treatment Trial#USA#Ulcerative_Colitis#Wilmington#Earendil_Labs#HXN-1001
Earendil Labs Marks Milestone with First Patient Doses in IBD Treatment Trial
Earendil Labs has begun its Phase IIa trial for HXN-1001 in ulcerative colitis patients, a major step towards innovative IBD treatments.
third-news.com
April 2, 2026 at 11:12 AM
newsen.bsky.social
Earendil Labs Launches Phase 1 Study of Innovative Anti-TL1A Antibody for IBD Treatment#United_States#IBD_treatment#Middletown#Earendil_Labs#HXN-1001
Earendil Labs Launches Phase 1 Study of Innovative Anti-TL1A Antibody for IBD Treatment
Earendil Labs has commenced a Phase 1 trial for HXN-1001, a next-generation anti-TL1A antibody aimed at treating inflammatory bowel diseases, showcasing innovative biotech advancements.
third-news.com
July 10, 2025 at 11:09 AM
l2plabs.bsky.social
Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis
WILMINGTON, Del., April 2, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a Phase IIa clinical trial of HXN-1001, a half-life extended anti-TL1A antibody, in patients with...
dlvr.it
April 2, 2026 at 11:03 AM
l2plabs.bsky.social
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody
MIDDLETOWN, Del., July 10, 2025 /PRNewswire/ -- Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety, tolerability,...
dlvr.it
July 10, 2025 at 11:16 AM